智通财经APP讯，石药集团(01093)发布公告，集团开发的GLP -1 / GIP受体双偏向性激动多肽注射液( SYH2069注射液 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。此前，该 产品亦已获得美国食品药品监督管理局(FDA)批准在美国开展临床试验。 本 次 获 批 的 临 床 适 应 症 为 肥 胖 或 超 重 合 并 至 少 一 种 体 重 相 关 合 并 症 人 群 的 体 重 管 理 。 此外，该产品亦具备用于改善成人2型糖尿病(T2DM)患者的血糖控制的潜力，具有较高的临床开发 价值。 该 产 品 有 望 成 为 中 国 首 款 进 入 临 床 阶 段 的 GLP -1 / GIP 受 体 双 偏 向 激 动 剂 ， 可 选 择 性 激 活 c AMP通路，显著降低b-arrestin募集，从而减少受体内吞及脱敏，提高药效和效果持续性。同 时，结合长半衰期修饰平台技术，该产品能实现更深度、更持久的减重效果。在饮食诱导肥胖(DIO)小 鼠和非人灵长类的研究中，该产品在减重及代谢改善方面的效果均显著优于同类上市产品。非人灵长类 重复给药毒理研究显示，该产品耐受性良好，未观 ...

该产品是一种高选择性强效醛固酮合成酶抑制剂(ASI)，可有效降低血浆醛固酮水平，且不影响皮质醇 水平。本次获批的临床适应症为未控制高血压和原发性醛固酮增多症。临床前研究显示，该产品可选择 性抑制醛固酮合成酶活性，在动物疾病模型中显著降低血浆醛固酮水平，并剂量依赖性地降低高血压模 型的血压，同时不影响皮质醇水平。该产品具有良好的药代动力学(PK)特性和安全性，使其具备成为一 款同类最优(best-in-class)药物的潜力。目前，集团已在国内外提交了该产品的多项专利申请。 智通财经APP讯，石药集团(01093)发布公告，集团开发的化药1类新药强效醛固酮合成酶抑制剂( SYH2072片 )已获得中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。 鉴于醛固酮合成酶抑制剂的临床需求广阔，该产品具有较高的临床开发价值，有望为未控制高血压和原 发性醛固酮增多症患者提供新的治疗选择。 ...

Core Viewpoint - The approval of the combination drug by the National Medical Products Administration of China marks a significant advancement in diabetes treatment, providing a new therapeutic option for patients with type 2 diabetes [1][2]. Group 1: Product Approval and Composition - The product, a combination of Ploglitazone, Dapagliflozin, and Metformin, is the first of its kind globally to receive clinical trial approval [1]. - Ploglitazone is a DPP-4 inhibitor that enhances insulin secretion and improves glucose sensitivity [1]. - Dapagliflozin is an SGLT2 inhibitor that promotes urinary glucose excretion by reducing glucose reabsorption [1]. - Metformin is a biguanide that improves glucose tolerance and lowers both fasting and postprandial blood glucose levels [1]. Group 2: Clinical Application and Benefits - The approved clinical indication is for use in adults with type 2 diabetes who have inadequate blood sugar control with Metformin alone, in conjunction with diet and exercise [2]. - The complementary mechanisms of the three-drug combination effectively address multiple pathophysiological aspects of diabetes, enhancing blood sugar control [2]. - The product is expected to simplify treatment regimens, reduce the number of medications needed, and improve patient adherence to therapy, indicating high clinical development value [2].

Core Viewpoint - The approval of SYH2069 injection by the National Medical Products Administration of China marks a significant milestone for the company, as it is set to be the first GLP-1/GIP receptor dual agonist to enter clinical trials in China, following its prior approval by the FDA for trials in the United States [1][1]. Group 1: Product Development - SYH2069 injection is designed to selectively activate the cAMP pathway, significantly reducing b-arrestin recruitment, which in turn minimizes receptor internalization and desensitization, enhancing drug efficacy and duration of effect [1][1]. - The product incorporates a long half-life modification platform technology, enabling deeper and more sustained weight loss effects compared to existing products [1][1]. Group 2: Clinical Research Findings - In studies involving diet-induced obesity (DIO) mice and non-human primates, SYH2069 demonstrated significantly superior weight loss and metabolic improvement effects compared to similar marketed products [1][1]. - Toxicology studies in non-human primates indicated good tolerability of the product, with no observed vomiting or gastrointestinal adverse reactions [1][1]. Group 3: Clinical Application and Potential - The approved clinical indication for SYH2069 is weight management in individuals who are overweight or obese with at least one weight-related comorbidity [1][1]. - The product also shows potential for improving blood glucose control in adults with type 2 diabetes mellitus (T2DM), indicating high clinical development value [1][1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 該產品是一種高選擇性強效醛固酮合成酶抑制劑(ASI)，可有效降低血漿醛固酮水平，且不 影響皮質醇水平。本次獲批的臨床適應症為未控制高血壓和原發性醛固酮增多症。臨床前 研究顯示，該產品可選擇性抑制醛固酮合成酶活性，在動物疾病模型中顯著降低血漿醛固 酮水平，並劑量依賴性地降低高血壓模型的血壓，同時不影響皮質醇水平。該產品具有良 好的藥代動力學(PK)特性和安全性，使其具備成為一款同類最優(best-in-class)藥物的潛力。 目前，本集團已在國內外提交了該產品的多項專利申請。 鑒於醛固酮合成酶抑制劑的臨床需求廣闊，該產品具有較高的臨床開發價值，有望為未控 制高血壓和原發性醛固酮增多症患者提供新的治療選擇。 承董事會命 石藥集團有限公司 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 強效醛 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的普盧格列汀達格列淨二甲雙胍緩釋片（「該產品」）已獲中華人民共和國國 家藥品監督管理局批准，可在中國開展臨床試驗。 該產品為全球首款獲批臨床的由普盧格列汀、達格列淨和鹽酸二甲雙胍組成的三藥聯合複 方製劑。普盧格列汀是一種二肽基肽酶-4（「DPP -4」）抑制劑，通過抑制DPP -4，使內源性活 性胰高血糖素樣肽-1 (GLP -1)水平升高，從而增強β細胞和α細胞對葡萄糖的敏感性，增加 葡 萄 糖 刺 激 的 胰 島 素 分 泌 ， 並 增 強 葡 萄 糖 對 胰 高 血 糖 素 分 泌 的 抑 制 作 用 ， 進 而 改 善 高 血 糖。達格列淨是一種鈉—葡萄糖協同轉運蛋 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 GLP -1 / GIP受體雙偏向性激動多肽注射液（SYH2069注射液） 在中國獲臨床試驗批准 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 布，本集團開發的GLP -1 / GIP受體雙偏向性激動多肽注射液（ SYH2069注射液 ）（「該產品」）已 獲得中華人民共和國國家藥品監督管理局批准，可在中國開展臨床試驗。此前，該產品亦 已獲得美國食品藥品監督管理局(FDA)批准在美國開展臨床試驗。 本 次 獲 批 的 臨 床 適 應 症 為 肥 胖 或 超 重 合 併 至 少 一 種 體 重 相 關 合 併 症 人 群 的 體 重 管 理 ...

Group 1 - The core viewpoint is that the Chinese healthcare industry is undergoing a profound transformation characterized by technological breakthroughs, innovative models, and social responsibility, culminating in a value evolution by 2025 [1] - The competition in the healthcare sector has expanded from mere technology or scale to a comprehensive comparison of innovation ecosystems, social responsibility, and sustainable development capabilities [1] - The 2025 Financial Innovation Economic Awards aim to recognize companies that embody a long-term perspective, support innovation, and safeguard life in the evolving healthcare landscape [1] Group 2 - A significant trend is that China is transitioning from being the largest medical application market to a source of cutting-edge innovation and solution incubation [2] - Notable events, such as GE Healthcare's global debut of the ExpertX quantum CT and significant R&D investments by companies like Hengrui Medicine and Innovent Biologics, indicate a shift from "fast following" to "source innovation" in Chinese healthcare [2] - Chinese companies are embedding "Chinese innovation" into the global R&D value chain through licensing and co-development models, while multinational companies are positioning China as a global R&D center [2] Group 3 - The boundaries of the healthcare industry are being redefined as the "Healthy China" strategy is implemented and public health awareness rises [3] - There is an accelerating integration of traditional healthcare and the broader health consumption market, with companies shifting focus from single products to comprehensive health solution ecosystems [4] - Companies like Yiling Pharmaceutical and Amway are transforming their business models to provide holistic health solutions, emphasizing a patient-centered approach [4] Group 4 - Leading companies are embedding social responsibility into their operational DNA, transforming philanthropy from an "add-on" to a "must-have" in their business strategies [4][5] - Initiatives such as Stryker's tree planting efforts and Tianjin's grassroots medical capacity building demonstrate a commitment to sustainable practices that create a positive impact on society [4] - The concept of "value co-existence" is highlighted, where corporate growth is closely linked to community health, environmental sustainability, and medical equity [5] Group 5 - The healthcare industry in 2025 will experience advancements driven by AI, precision medicine, and cell therapy, while also returning to the essence of healthcare, patient experience, and social responsibility [6] - The industry will continue to seek a balance between technological innovation and humanistic care, commercial expansion and social responsibility, as well as globalization and localization [6]

Group 1 - In December, several leading pharmaceutical companies experienced significant executive changes, including Guoyao Holdings, BeiGene, and Zhendong Pharmaceutical [1][2] - Kexin Pharmaceutical announced the election of Li Hongfu as the chairman of its fourth board of directors on December 1 [1] - Kang En Bei reported that Jiang Yi resigned from multiple positions, including chairman, on December 6 due to work adjustments [1] Group 2 - WuXi AppTec appointed Tian Feng as the CEO and executive director, effective December 29, 2025 [2] - Alibaba Health announced the resignation of Zhu Shunyan as non-executive director and chairman, with current CEO Shen Difan taking over as chairman [2] - Sangfor Technologies reported the resignation of core technical personnel, Weng Zhibing, from all positions in its wholly-owned subsidiary on December 16 [2] Group 3 - Zhendong Pharmaceutical announced that Yang Lianmin resigned from his positions due to reaching retirement age on December 18 [2] - BeiGene appointed Dr. Wang Lai as president and global head of R&D, effective December 19 [2] - Guoyao Holdings announced Jin Bin as the new chairman on December 19, following the resignation of Zhao Bingxiang [2] Group 4 - Shijiazhuang Pharmaceutical Group reported that Zhang Cuilong stepped down from multiple roles, while Cai Lei was appointed as vice chairman and CEO on December 19 [3] - Weichuang Bio announced the appointment of Li Jianxun as general manager, while Chairman Lu Xianping stepped down from the general manager role on December 23 [3] - Shandong Pharmaceutical Glass reported that Chairman Hu Yonggang resigned from all positions due to age, with General Manager Zhang Jun taking over the chairman's responsibilities on December 24 [3]

Core Viewpoint - The Hong Kong stock market opened positively, with the Hang Seng Index rising, but the innovative drug sector unexpectedly declined, indicating potential volatility in this segment [1]. Group 1: Market Performance - The Hang Seng Index showed a rise, with the Hang Seng Technology Index increasing by over 2% at one point [1]. - The Hong Kong Stock Connect innovative drug ETF (520880) fell by more than 1.5% during trading, with major stocks like CSPC Pharmaceutical Group and CanSino Biologics dropping over 1% [1]. Group 2: Investment Sentiment - Despite the decline, the Hong Kong Stock Connect innovative drug ETF (520880) continued to trade at a premium, suggesting that there may be investors looking to buy on dips [2]. - Analysts remain optimistic about domestic innovative drugs, noting that the past two years have been significant for Chinese innovative drugs entering international markets, with record highs in both the number and value of licensing deals [3]. Group 3: Future Outlook - The industry is expected to see continued positive catalysts in 2026, including major industry conferences, significant business development transactions, and breakthroughs in new technologies [3]. - The innovative drug sector has been in a phase of adjustment since September, with risks being sufficiently released, leading to improved cost-effectiveness for investments [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) has a significant concentration in leading companies, with the top ten stocks accounting for over 72% of its weight, indicating a strong representation of the innovative drug sector [4]. - The ETF is designed to exclude CXO companies, focusing solely on innovative drug firms, which enhances its appeal to investors seeking pure exposure to this segment [3][4].